GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (NAS:VYGR) » Definitions » Beneish M-Score

Voyager Therapeutics (Voyager Therapeutics) Beneish M-Score : 21.93 (As of May. 11, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Voyager Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 21.93 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Voyager Therapeutics's Beneish M-Score or its related term are showing as below:

VYGR' s Beneish M-Score Range Over the Past 10 Years
Min: -5.13   Med: -2.02   Max: 21.93
Current: 21.93

During the past 11 years, the highest Beneish M-Score of Voyager Therapeutics was 21.93. The lowest was -5.13. And the median was -2.02.


Voyager Therapeutics Beneish M-Score Historical Data

The historical data trend for Voyager Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics Beneish M-Score Chart

Voyager Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.15 -0.29 -5.13 -3.75 21.93

Voyager Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.75 20.32 4.81 -2.59 21.93

Competitive Comparison of Voyager Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Voyager Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyager Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Beneish M-Score falls into.



Voyager Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Voyager Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 21.6253+0.528 * 1+0.404 * 0.477+0.892 * 6.1118+0.115 * 1.2146
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.1892+4.679 * 0.154885-0.327 * 0.3985
=21.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $84.5 Mil.
Revenue was 90.061 + 4.614 + 4.853 + 150.48 = $250.0 Mil.
Gross Profit was 90.061 + 4.614 + 4.853 + 150.48 = $250.0 Mil.
Total Current Assets was $319.7 Mil.
Total Assets was $351.3 Mil.
Property, Plant and Equipment(Net PPE) was $30.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $4.4 Mil.
Selling, General, & Admin. Expense(SGA) was $35.8 Mil.
Total Current Liabilities was $64.5 Mil.
Long-Term Debt & Capital Lease Obligation was $17.1 Mil.
Net Income was 56.395 + -25.901 + -22.208 + 124.044 = $132.3 Mil.
Non Operating Income was 0 + 0 + 0.003 + 0 = $0.0 Mil.
Cash Flow from Operations was -23.76 + -21.051 + -0.835 + 123.565 = $77.9 Mil.
Total Receivables was $0.6 Mil.
Revenue was -1.55 + 41.086 + 0.712 + 0.658 = $40.9 Mil.
Gross Profit was -1.55 + 41.086 + 0.712 + 0.658 = $40.9 Mil.
Total Current Assets was $124.5 Mil.
Total Assets was $159.4 Mil.
Property, Plant and Equipment(Net PPE) was $33.3 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.2 Mil.
Selling, General, & Admin. Expense(SGA) was $31.0 Mil.
Total Current Liabilities was $72.6 Mil.
Long-Term Debt & Capital Lease Obligation was $20.3 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(84.455 / 250.008) / (0.639 / 40.906)
=0.337809 / 0.015621
=21.6253

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(40.906 / 40.906) / (250.008 / 250.008)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (319.684 + 30.004) / 351.281) / (1 - (124.499 + 33.342) / 159.356)
=0.004535 / 0.009507
=0.477

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=250.008 / 40.906
=6.1118

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6.191 / (6.191 + 33.342)) / (4.441 / (4.441 + 30.004))
=0.156603 / 0.12893
=1.2146

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(35.822 / 250.008) / (30.98 / 40.906)
=0.143283 / 0.757346
=0.1892

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((17.093 + 64.508) / 351.281) / ((20.294 + 72.591) / 159.356)
=0.232296 / 0.582877
=0.3985

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(132.33 - 0.003 - 77.919) / 351.281
=0.154885

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Voyager Therapeutics has a M-score of 21.93 signals that the company is likely to be a manipulator.


Voyager Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Voyager Therapeutics (Voyager Therapeutics) Business Description

Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.
Executives
Todd Alfred Carter officer: Chief Scientific Officer C/O VOYAGER THERAPEUTICS, INC., 64 SIDNEY STREET, CAMBRIDGE MA 02139
Robin Swartz officer: Chief Operating Officer C/O VOYAGER THERAPEUTICS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Peter P. Pfreundschuh officer: Chief Financial Officer C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sandell Jacquelyn Fahey officer: Chief Legal Officer C/O VOYAGER THERAPEUTICS, INC., 64 SIDNEY STREET, CAMBRIDGE MA 02139
George A Scangos director C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Alfred Sandrock director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Robert W. Hesslein officer: Senior VP & General Counsel C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Jude Onyia director C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Neurocrine Biosciences Inc 10 percent owner 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Third Rock Ventures Iii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Grace Colon director C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Glenn Pierce director
Michael J Higgins director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140